CStone Pharmaceuticals

As of December 31, 2025, CStone Pharmaceuticals carries a market capitalization of 7.77B, placing it among publicly traded companies globally. Its enterprise value stands at 7.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CStone Pharmaceuticals's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, CStone Pharmaceuticals has 1.47B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, CStone Pharmaceuticals maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, CStone Pharmaceuticals's stock has declined approximately 31.09% over the past 52 weeks. The 50-day moving average sits at 5.58, while the 200-day moving average is 6.21.

As of December 31, 2025, CStone Pharmaceuticals holds 1.02B in cash and equivalents against 387.86M in total debt, resulting in a net debt position of -457.73M. Total book value stands at 686.40M, with working capital of 671.03M providing operational flexibility.